UNASSIGNED: Obesity is associated with a worse @entity0 prognosis, while greater breast @entity5 @entity172 receptor beta ( @entity1783 ) expression is correlated with improved therapy response and survival. The objective of this study was to determine the impact of @entity28 on @entity0 cell @entity1783 expression, which is currently unknown. We utilized an in vitro model of @entity28 in which @entity0 cells were exposed to patient serum pooled by body mass index category ( @entity28 ( @entity28 ): >= 30 kg/m2; normal weight (N): 18.5-24.9 kg/m2). Four @entity1 @entity5 cell lines representing the major @entity0 subtypes (SKBR3, MCF-7, ZR75, MDA-MB-231) and @entity5 cells from @entity6584 -neu @entity19 were used. @entity1783 expression, assessed by qPCR and western blotting, was suppressed in the two @entity1722 -overexpressing cell lines (SKBR3, @entity6584 -neu) following @entity28 versus N sera exposure, but did not vary in the other cell lines. Expression of @entity588 and @entity4910 , two genes negatively regulated by @entity1783 , was elevated in SKBR3 cells following exposure to @entity28 versus N sera, but this difference was eliminated when the @entity1783 gene was silenced with siRNA. Herceptin, a @entity1722 antagonist, and siRNA to @entity1722 were used to evaluate the role of @entity1722 in sera-induced @entity1783 modulation. SKBR3 cell treatment with @entity28 sera plus Herceptin increased @entity1783 expression three-fold. Similar results were obtained when @entity1722 expression was silenced with siRNA. @entity28 sera also promoted greater SKBR3 cell viability and growth, but this variance was not present when @entity1783 was silenced or the cells were modified to overexpress @entity1783 . Based on this data, we conclude that @entity28 -associated systemic factors suppress @entity1783 expression in @entity0 cells via a @entity1722 -mediated pathway, leading to greater cell viability and growth. Elucidation of the mechanism(s) mediating this effect could provide important insights into how @entity1783 expression is regulated as well as how @entity28 promotes a @entity146 .

Obesity Suppresses @entity172 Receptor Beta Expression in @entity0 Cells via a XXXX -Mediated Pathway.

@entity172 :: ('MESH:D004967', 'Chemical') :: ['estrogen'] @entity1 :: ('9606', 'Species') :: ['human'] @entity6584 :: ('11757', 'Species') :: ['MMTV'] @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer'] @entity28 :: ('MESH:D009765', 'Disease') :: ['obese', 'obesity', 'OB'] @entity588 :: ('596', 'Gene') :: ['Bcl-2'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'mammary tumor'] @entity19 :: ('10090', 'Species') :: ['mice'] @entity146 :: ('MESH:D001523', 'Disease') :: ['more aggressive disease'] @entity4910 :: ('595', 'Gene') :: ['cyclin D1'] @entity1783 :: ('2100', 'Gene') :: ['ERb'] @entity1722 :: ('2064', 'Gene') :: ['HER2']
@entity1722 :: (2064,Gene) :: ['HER2']
